Enanta Pharmaceuticals (NASDAQ:ENTA) Posts Earnings Results, Beats Estimates By $0.12 EPS

Enanta Pharmaceuticals (NASDAQ:ENTA) announced its quarterly earnings results on Monday. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.12, FiscalAI reports. The company had revenue of $18.62 million during the quarter, compared to analyst estimates of $16.14 million. Enanta Pharmaceuticals had a negative net margin of 125.36% and a negative return on equity of 93.76%.

Enanta Pharmaceuticals Stock Performance

NASDAQ ENTA opened at $13.83 on Tuesday. Enanta Pharmaceuticals has a 52-week low of $4.09 and a 52-week high of $17.15. The stock has a market cap of $401.35 million, a PE ratio of -3.61 and a beta of 0.98. The firm has a 50-day moving average of $14.11 and a 200-day moving average of $11.34.

Analyst Ratings Changes

Several research firms have recently weighed in on ENTA. JPMorgan Chase & Co. assumed coverage on Enanta Pharmaceuticals in a report on Friday, November 14th. They set an “overweight” rating and a $17.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Wednesday, January 21st. Finally, HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Enanta Pharmaceuticals in a report on Friday, January 9th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $20.33.

Insider Activity at Enanta Pharmaceuticals

In related news, CEO Jay R. Luly sold 4,743 shares of the firm’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $14.23, for a total transaction of $67,492.89. Following the transaction, the chief executive officer directly owned 858,026 shares of the company’s stock, valued at approximately $12,209,709.98. This trade represents a 0.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Tara Lynn Kieffer sold 2,106 shares of the stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $14.23, for a total transaction of $29,968.38. Following the transaction, the insider owned 30,620 shares in the company, valued at approximately $435,722.60. The trade was a 6.44% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 11,961 shares of company stock worth $170,149 in the last ninety days. 11.48% of the stock is owned by company insiders.

Institutional Trading of Enanta Pharmaceuticals

Large investors have recently modified their holdings of the stock. Ameriprise Financial Inc. increased its holdings in Enanta Pharmaceuticals by 8.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 18,007 shares of the biotechnology company’s stock valued at $216,000 after buying an additional 1,383 shares during the period. Man Group plc acquired a new stake in shares of Enanta Pharmaceuticals during the 3rd quarter worth approximately $481,000. Bridgeway Capital Management LLC increased its stake in Enanta Pharmaceuticals by 50.8% in the second quarter. Bridgeway Capital Management LLC now owns 29,700 shares of the biotechnology company’s stock valued at $225,000 after acquiring an additional 10,000 shares during the last quarter. Marshall Wace LLP increased its stake in Enanta Pharmaceuticals by 0.8% in the second quarter. Marshall Wace LLP now owns 857,412 shares of the biotechnology company’s stock valued at $6,482,000 after acquiring an additional 6,522 shares during the last quarter. Finally, Invesco Ltd. raised its position in Enanta Pharmaceuticals by 4.3% during the second quarter. Invesco Ltd. now owns 62,884 shares of the biotechnology company’s stock valued at $475,000 after purchasing an additional 2,607 shares in the last quarter. 94.99% of the stock is owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.